BioCatalyst

Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab — catalyst calendar

1 verified catalyst event(s) referencing Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab, each linked to its official source. Verified as of 2026-08-06.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-10-23
in 3mo
ESTIMATED
 READOUT
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combinati
Phase 2 · Carcinoma, Non-Small-Cell Lung
 AZN ASTRAZENECA PLC Durvalumab, Tremelimumab, Pemetrexed, Pe ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.